Total Payments
$747,055
2024 Payments
$155,862
Companies
34
Transactions
1,729
Medicare Patients
2,394
Medicare Billing
$373,359
Payment Breakdown by Category
Other$438,485 (58.7%)
Research$195,509 (26.2%)
Travel$41,488 (5.6%)
Food & Beverage$40,813 (5.5%)
Consulting$30,668 (4.1%)
Education$93.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $420,470 | 268 | 56.3% |
| Unspecified | $195,509 | 14 | 26.2% |
| Travel and Lodging | $41,488 | 101 | 5.6% |
| Food and Beverage | $40,813 | 1,321 | 5.5% |
| Consulting Fee | $30,668 | 13 | 4.1% |
| Honoraria | $14,640 | 1 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,375 | 5 | 0.5% |
| Education | $93.19 | 6 | 0.0% |
Payments by Type
General
$551,546
1,715 transactions
Research
$195,509
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $200,602 | 58 | $0 (2024) |
| Lilly USA, LLC | $180,375 | 359 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $116,677 | 347 | $0 (2024) |
| Novo Nordisk Inc | $109,702 | 309 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $66,546 | 179 | $0 (2024) |
| Corcept Therapeutics | $26,523 | 38 | $0 (2024) |
| Abbott Laboratories | $18,190 | 71 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $14,613 | 85 | $0 (2023) |
| Amgen Inc. | $7,467 | 66 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,637 | 63 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $155,862 | 165 | Eli Lilly and Company ($95,917) |
| 2023 | $49,460 | 202 | Lilly USA, LLC ($16,194) |
| 2022 | $116,598 | 240 | Novo Nordisk Inc ($48,118) |
| 2021 | $154,513 | 194 | Eli Lilly and Company ($86,960) |
| 2020 | $59,630 | 156 | Lilly USA, LLC ($19,186) |
| 2019 | $75,365 | 291 | Lilly USA, LLC ($34,109) |
| 2018 | $80,025 | 275 | Lilly USA, LLC ($19,900) |
| 2017 | $55,602 | 206 | Lilly USA, LLC ($24,816) |
All Payment Transactions
1,729 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: Diabetes | ||||||
| 12/16/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $19.52 | General |
| Category: Insulin Pump | ||||||
| 12/13/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $7.53 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $30.09 | General |
| Category: Endocrinology | ||||||
| 12/09/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $5.29 | General |
| Category: Diabetes Care | ||||||
| 12/09/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $1.49 | General |
| Category: Diabetes Care | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: DIABETES | ||||||
| 11/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $107.15 | General |
| Category: Diabetes Care | ||||||
| 11/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $2.88 | General |
| Category: Diabetes Care | ||||||
| 11/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $2.36 | General |
| Category: Diabetes Care | ||||||
| 11/06/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $82.00 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Bone Health | ||||||
| 10/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $33.42 | General |
| Category: DIABETES | ||||||
| 10/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $11.04 | General |
| Category: Cardio-renal | ||||||
| 10/28/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Diabetes | ||||||
| 10/18/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $4.01 | General |
| Category: Diabetes Care | ||||||
| 10/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.95 | General |
| Category: DIABETES | ||||||
| 10/10/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes Care | ||||||
| 10/09/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Endocrinology | ||||||
| 10/09/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Endocrinology | ||||||
| 10/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: DIABETES | ||||||
| 10/05/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $18.97 | General |
| Category: Insulin Pump | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $87,406 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $49,723 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | Eli Lilly and Company | $27,155 | 2 |
| PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | Eli Lilly and Company | $15,502 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $12,773 | 4 |
| A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | Eli Lilly and Company | $2,152 | 1 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $600.01 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $198.36 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 691 | 1,295 | $269,013 | $113,576 |
| 2022 | 8 | 729 | 1,328 | $253,125 | $107,019 |
| 2021 | 5 | 474 | 948 | $200,342 | $87,579 |
| 2020 | 6 | 500 | 908 | $177,037 | $65,185 |
Total Patients
2,394
Total Services
4,479
Medicare Billing
$373,359
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 362 | 831 | $180,177 | $77,377 | 42.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 135 | 212 | $29,579 | $13,190 | 44.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $25,622 | $9,306 | 36.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 52 | $15,923 | $7,412 | 46.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 50 | 50 | $11,167 | $4,460 | 39.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 37 | 70 | $6,545 | $1,831 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 320 | 762 | $165,356 | $69,366 | 41.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 109 | 171 | $22,270 | $11,645 | 52.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 88 | 88 | $28,165 | $11,217 | 39.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 53 | $16,096 | $7,786 | 48.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 43 | 43 | $9,603 | $3,805 | 39.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 35 | 67 | $6,265 | $1,771 | 28.3% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 11 | 11 | $3,084 | $1,024 | 33.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 91 | 133 | $2,286 | $406.01 | 17.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 298 | 727 | $158,027 | $70,543 | 44.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 58 | 58 | $19,443 | $7,205 | 37.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 74 | 109 | $14,319 | $6,875 | 48.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 27 | 27 | $6,030 | $2,242 | 37.2% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 17 | 27 | $2,525 | $712.79 | 28.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 256 | 624 | $137,399 | $50,479 | 36.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 55 | 55 | $17,555 | $6,912 | 39.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 62 | 95 | $13,190 | $5,021 | 38.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 26 | 26 | $5,807 | $2,078 | 35.8% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 11 | 16 | $1,496 | $420.12 | 28.1% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2020 | 90 | 92 | $1,590 | $275.47 | 17.3% |
About Dr. Alan Parsa, M.D
Dr. Alan Parsa, M.D is a Internal Medicine healthcare provider based in Honolulu, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2010. The National Provider Identifier (NPI) number assigned to this provider is 1215268362.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Parsa, M.D has received a total of $747,055 in payments from pharmaceutical and medical device companies, with $155,862 received in 2024. These payments were reported across 1,729 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($420,470).
As a Medicare-enrolled provider, Parsa has provided services to 2,394 Medicare beneficiaries, totaling 4,479 services with total Medicare billing of $373,359. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Honolulu, HI
- Active Since 01/28/2010
- Last Updated 11/26/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215268362
Products in Payments
- JARDIANCE (Drug) $148,185
- TRULICITY (Drug) $122,487
- FARXIGA (Drug) $62,853
- Ozempic (Drug) $32,945
- MOUNJARO (Drug) $32,434
- Rybelsus (Drug) $30,645
- RYBELSUS (Drug) $27,913
- Korlym (Drug) $26,523
- FREESTYLE LIBRE 3 (Device) $8,030
- TOUJEO (Drug) $7,594
- EVENITY (Biological) $6,953
- SOLIQUA (Drug) $6,426
- FREESTYLE LIBRE 2 (Device) $6,210
- FreeStyle Libre Pro (Device) $2,700
- Kerendia (Drug) $2,622
- BYDUREON (Drug) $2,175
- TRADJENTA (Drug) $870.11
- FREESTYLE LIBRE PRO (Device) $675.00
- Saxenda (Drug) $573.35
- FREESTYLE LIBRE (Device) $498.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Honolulu
Dr. Keith Woo, M.d, M.D
Internal Medicine — Payments: $183,455
Internal Medicine $183,455
Dr. Charles Zerez, M.d, M.D
Internal Medicine — Payments: $97,493
Internal Medicine $97,493
Joshua Tan, M.d, M.D
Internal Medicine — Payments: $94,447
Internal Medicine $94,447
James Lumeng, M.d, M.D
Internal Medicine — Payments: $66,956
Internal Medicine $66,956
Jose Deleon, M.d, M.D
Internal Medicine — Payments: $55,692
Internal Medicine $55,692
Dr. Boyuan Cao, M.d, M.D
Internal Medicine — Payments: $44,127
Internal Medicine $44,127